London-listed Shire to acquire American biotech company Dyax for $5.9bn
London-listed biopharmaceutical company Shire has struck a deal to buy Dyax, an American biotech company for $5.9bn. Post the deal, Shire will be the world's biggest manufacturer of rare disease drugs by sales.Dyax, having achieved a breakthrough in a rare disease treatment, seemed attractive to Shire as its products would have otherwise rivalled directly with portions of the London-listed company's portfolio. The drug, codenamed 'DX-2930', has completed its early-stage trials. In July, it was fast-tracked Read more [...]